Detail akcie MBX Bio Rg online

Business Summary: MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, MBX Biosciences Inc revenues was not reported. Net loss increased 40% to $64.9M. Higher net loss reflects single segment for the purposes of assessing performance and loss increase of 46% to $72.3M, United States segment loss increase of 46% to $72.3M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.43 to -$1.93.